Multi-omics analysis of disulfidptosis regulators and therapeutic potential reveals glycogen synthase 1 as a disulfidptosis triggering target for triple-negative breast cancer
© 2024 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd..
Disruption of disulfide homeostasis during biological processes can have fatal consequences. Excess disulfides induce cell death in a novel manner, termed as "disulfidptosis." However, the specific mechanism of disulfidptosis has not yet been elucidated. To determine the cancer types sensitive to disulfidptosis and outline the corresponding treatment strategies, we firstly investigated the crucial functions of disulfidptosis regulators pan-cancer at multi-omics levels. We found that different tumor types expressed dysregulated levels of disulfidptosis regulators, most of which had an impact on tumor prognosis. Moreover, we calculated the disulfidptosis activity score in tumors and validated it using multiple independent datasets. Additionally, we found that disulfidptosis activity was correlated with classic biological processes and pathways in various cancers. Disulfidptosis activity was also associated with tumor immune characteristics and could predict immunotherapy outcomes. Notably, the disulfidptosis regulator, glycogen synthase 1 (GYS1), was identified as a promising target for triple-negative breast cancer and validated via in vitro and in vivo experiments. In conclusion, our study elucidated the complex molecular phenotypes and clinicopathological correlations of disulfidptosis regulators in tumors, laying a solid foundation for the development of disulfidptosis-targeting strategies for cancer treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
MedComm - 5(2024), 3 vom: 27. März, Seite e502 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xie, Jindong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Disulfidptosis |
|---|
| Anmerkungen: |
Date Revised 01.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/mco2.502 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369100786 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369100786 | ||
| 003 | DE-627 | ||
| 005 | 20240301232943.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/mco2.502 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1313.xml |
| 035 | |a (DE-627)NLM369100786 | ||
| 035 | |a (NLM)38420162 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xie, Jindong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multi-omics analysis of disulfidptosis regulators and therapeutic potential reveals glycogen synthase 1 as a disulfidptosis triggering target for triple-negative breast cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd. | ||
| 520 | |a Disruption of disulfide homeostasis during biological processes can have fatal consequences. Excess disulfides induce cell death in a novel manner, termed as "disulfidptosis." However, the specific mechanism of disulfidptosis has not yet been elucidated. To determine the cancer types sensitive to disulfidptosis and outline the corresponding treatment strategies, we firstly investigated the crucial functions of disulfidptosis regulators pan-cancer at multi-omics levels. We found that different tumor types expressed dysregulated levels of disulfidptosis regulators, most of which had an impact on tumor prognosis. Moreover, we calculated the disulfidptosis activity score in tumors and validated it using multiple independent datasets. Additionally, we found that disulfidptosis activity was correlated with classic biological processes and pathways in various cancers. Disulfidptosis activity was also associated with tumor immune characteristics and could predict immunotherapy outcomes. Notably, the disulfidptosis regulator, glycogen synthase 1 (GYS1), was identified as a promising target for triple-negative breast cancer and validated via in vitro and in vivo experiments. In conclusion, our study elucidated the complex molecular phenotypes and clinicopathological correlations of disulfidptosis regulators in tumors, laying a solid foundation for the development of disulfidptosis-targeting strategies for cancer treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a disulfidptosis | |
| 650 | 4 | |a pan‐cancer | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a single‐cell RNA‐seq | |
| 650 | 4 | |a tumor microenvironment | |
| 700 | 1 | |a Deng, Xinpei |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Hongbo |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Peng |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Ning, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Yuhui |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Yuying |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Hailin |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Manbo |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Xiaoming |e verfasserin |4 aut | |
| 700 | 1 | |a Zou, Yutian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t MedComm |d 2020 |g 5(2024), 3 vom: 27. März, Seite e502 |w (DE-627)NLM314118411 |x 2688-2663 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2024 |g number:3 |g day:27 |g month:03 |g pages:e502 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/mco2.502 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2024 |e 3 |b 27 |c 03 |h e502 | ||